News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Nomura Lifts HANSOH PHARMA's TP to HKD25.64 on Product Licensing
HANSOH PHARMA (03692.HK) announced a collaboration with Regeneron (REGN.US), under which HANSOH PHARMA will grant Regeneron an exclusive worldwide (excluding Mainland China, Hong K...
Reset
Send
The window will close in 5 seconds
<Research>Nomura Lifts HANSOH PHARMA's TP to HKD25.64 on Product Licensing
Close
Recommend
3
Positive
6
Negative
3
 
SHORT SELL
 
STOCK INFO

HANSOH PHARMA (03692.HK)  +0.750 (+2.836%)    Short selling $41.24M; Ratio 18.679%   announced a collaboration with Regeneron (REGN.US)      , under which HANSOH PHARMA will grant Regeneron an exclusive worldwide (excluding Mainland China, Hong Kong, and Macau) license to develop, manufacture, and commercialize HS-20094. In return, HANSOH PHARMA will receive an upfront payment of USD80 million.

Nomura opined in its research report that HANSOH PHARMA's product licensing has reflected the recognition of its R&D capabilities, which is expected to boost its financial performance. The broker lifted its target price for the company from HKD19.86 to HKD25.64, while keeping the Neutral rating unchanged given the current expensive valuation.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-06 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Related NewsUOB Kay Hian Lifts HANSOH PHARMA's TP to HKD40 w/ Buy Rating

AAStocks Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.